bms-641988 bms-641988 bms-641988 is a nonsteroidal antiandrogen which was developed by bristol-myers squibb for the treatment of prostate cancer but was never marketed. it acts as a potent competitive antagonist of the androgen receptor (ar) (ki = 10 nm; ic50 = 56 nm). the drug was found to have 20-fold higher affinity for the ar than bicalutamide in mda-mb-453 cells, and showed 3- to 7-fold the antiandrogenic activity of bicalutamide in vitro. it may have some weak partial agonist activity at the androgen receptor. bms-641988 is transformed by cyp3a4 into bms-570511, and this metabolite is then reduced to bms-501949 by cytosolic reductases. all three compounds show similar antiandrogenic activity. in addition to its antiandrogenic activity, bms-641988 shows activity as a negative allosteric modulator of the gabaa receptor, and can produce seizures in animals at sufficiently high doses. it also shows some drug-induced qt prolongation. bms-641988 reached phase i clinical trials prior to the discontinuation of its development. the clinical development of bms-641988 was terminated due to the occurrence of a seizure in a patient during a phase i study. bms-641988clinical dataroutes ofadministrationby mouthdrug classnonsteroidal antiandrogenidentifiers iupac name n--4,7-dimethyl-1,3-dioxo-3a,5,6,7a-tetrahydro-octahydro-1h-4,7-epoxyisoindol-5-yl]ethanesulfonamide cas number1093276-09-5 573738-99-5pubchem cid24768935uniiw17m53y8imchebichebi:95017chemblchembl3932464comptox dashboard (epa)dtxsid70205969 chemical and physical dataformulac20h20f3n3o5smolar mass471.45 g·mol−13d model (jsmol)interactive image smiles ccs(=o)(=o)n1c2(3(1(o2)c)c(=o)n(c3=o)c4=cc(=c(c=c4)c#n)c(f)(f)f)c inchi inchi=1s/c20h20f3n3o5s/c1-4-32(29,30)25-13-8-18(2)14-15(19(13,3)31-18)17(28)26(16(14)27)11-6-5-10(9-24)12(7-11)20(21,22)23/h5-7,13-15,25h,4,8h2,1-3h3/t13-,14-,15+,18-,19+/m1/s1key:hynanjukemcyeq-highgglbsa-n